- What the FDA Is Actually Asking
- The 510(k) Pathway: Substantial Equivalence
- The PMA Pathway: Valid Scientific Evidence
- Key Differences at a Glance
- The De Novo Pathway: A Third Option Worth Knowing
- How Pathway Choice Shapes Your FIH Study
- Aligning FIH Trial Design to Your Pathway
- Practical Questions to Ask Before You Choose
- When Founders Get This Wrong
- FAQs
Choosing between a 510(k) and a Premarket Approval (PMA) is one of the most consequential decisions a medical device founder makes. Get it right early, and your clinical strategy, budget, and investor timeline all line up. Get it wrong, and you may spend 18 months collecting data that doesn't satisfy the evidentiary standard your pathway actually requires.
This article breaks down the core differences between the two pathways, how to determine which applies to your device, and what that choice means for your first-in-human trial design.
What the FDA Is Actually Asking
Both pathways exist to answer the same fundamental question: is this device safe and effective enough to be on the US market? The difference lies in how much evidence the FDA needs to reach that answer — and that requirement flows directly from how your device is classified.
The FDA assigns every medical device to one of three classes based on patient risk.
- Class I devices carry low risk. Most are exempt from premarket review entirely.
- Class II devices carry moderate risk. Most reach market through the 510(k) pathway.
- Class III devices carry the highest risk — typically because they sustain or support life, are implanted, or present an unreasonable risk of illness or injury. These require PMA.
Your device's classification is the starting point for everything else.
The 510(k) Pathway: Substantial Equivalence
A 510(k) submission asks the FDA to clear your device by demonstrating substantial equivalence to a legally marketed predicate. You're not proving safety and effectiveness in isolation — you're showing your device performs comparably to something already on the market.
What “substantially equivalent” means in practice
Your device must share the same intended use as the predicate and either the same technological characteristics, or different characteristics that don't raise new safety or effectiveness questions. That framing matters because it shapes what kind of clinical data — if any — you actually need to collect.
Many 510(k) submissions rely primarily on bench testing, biocompatibility data, and performance testing. When clinical data is required, it's typically a focused study rather than a full pivotal trial.
Timeline and workload
The FDA's standard review period for a 510(k) is 90 days from acceptance, though total elapsed time often runs longer when the agency issues additional information requests. For a device with a clear predicate and strong bench data, the 510(k) can be a relatively fast path to market.
The risk is predicate selection. A weak or distant predicate invites a Not Substantially Equivalent determination — which can push you toward De Novo or PMA territory without warning.
The PMA Pathway: Valid Scientific Evidence
A PMA requires you to demonstrate reasonable assurance of safety and effectiveness through valid scientific evidence. There's no predicate to point to. The FDA evaluates your device on its own merits, which means your clinical dataset needs to stand alone.
This is the pathway for Class III devices: implantable cardiac devices, certain neurological implants, high-risk diagnostics, and others where failure could cause serious harm.
What a PMA clinical program looks like
A PMA typically requires at least one well-controlled pivotal trial — often with a statistically powered sample size, defined primary endpoints, and a comparator arm. The FDA's review of that data is rigorous, and the agency may convene an advisory panel for high-profile submissions.
The IDE (Investigational Device Exemption) is the mechanism that allows you to collect pivotal data in the first place. Before you enroll a single patient in a significant-risk device study, you need an approved IDE. That application itself requires preliminary safety data — which is exactly where a first-in-human or early feasibility study fits in.
Timeline and investment
PMA is a longer, more expensive process than 510(k). Total development timelines from first-in-human to PMA approval can run five to ten years for complex devices. The clinical program alone typically spans multiple phases: an early feasibility study to establish safety signals, followed by a pivotal trial to generate primary effectiveness data.
For a startup, that timeline has direct implications for how you structure your FIH study and what evidence you need before your next funding round.
Key Differences at a Glance
| Factor | 510(k) | PMA |
|---|---|---|
| Device class | Primarily Class II | Class III |
| Standard of review | Substantial equivalence to a predicate | Valid scientific evidence of safety and effectiveness |
| Clinical data requirement | Often limited or none | Required; typically a pivotal trial |
| IDE required | Only for significant-risk studies | Yes, for pivotal and often for early feasibility |
| FDA review timeline | ~90 days (standard) | 180 days (after filing acceptance) |
| Post-approval requirements | Generally lighter | Ongoing post-approval studies common |
The De Novo Pathway: A Third Option Worth Knowing
If your device is genuinely novel, poses low to moderate risk, and has no valid predicate, De Novo is worth serious consideration. It creates a new device classification and, once granted, establishes your device as a predicate for future 510(k) submissions.
De Novo is not a shortcut. It requires more documentation than a standard 510(k), and the FDA's review period is longer. But for a first-of-kind device that doesn't belong in Class III, it's the appropriate route — and it avoids the burden of a full PMA.
How Pathway Choice Shapes Your FIH Study
Your regulatory pathway determines the evidentiary standard your clinical data must meet. That standard, in turn, determines what your first-in-human study actually needs to accomplish.
For a 510(k) device, your FIH study is often a relatively small early feasibility study designed to confirm safety signals and support predicate comparisons. Endpoints are narrower, enrollment targets are smaller, and the study can typically be completed faster.
For a PMA device, your FIH study is the first step in a longer clinical program. The FDA will evaluate it as part of the overall evidence package, and the data needs to be structured to support the IDE application for your pivotal trial. Endpoints, patient population, and follow-up duration all have to be designed with that pivotal study in mind from day one.
This is why FDA strategy alignment can't be an afterthought. Design your FIH study without anchoring it to your intended pathway, and you risk collecting data that doesn't move your program forward.
Aligning FIH Trial Design to Your Pathway
At bioaccess®, every study in the FIH-12™ program begins with FDA strategy alignment as the first of nine workstreams. The protocol is built around the sponsor's intended pathway — whether that's IDE, 510(k), De Novo, PMA, or HDE — so the clinical evidence package that comes out of the program is structured for the submission it needs to support.
Trials run in Panama, Colombia, El Salvador, Chile, and the Dominican Republic, where ethics and regulatory approvals are observed in 30 to 90 days, compared to 6 to 12 months in the US or EU. That speed matters when your runway is finite and your next funding milestone depends on having human data in hand.
The FIH-12™ program delivers a submission-ready evidence package within 12 months. All data is structured for FDA acceptance under 21 CFR 812.28, which governs the use of foreign clinical data in US submissions.
Practical Questions to Ask Before You Choose
Before committing to a pathway, work through these with your regulatory team:
What is your device's intended use, and does it match an existing predicate? If yes, 510(k) is likely your starting point. If no, you're looking at De Novo or PMA.
What risk class does the FDA assign to devices with your intended use? The FDA's product classification database is the first place to check. If your device type is consistently Class III, PMA is your pathway regardless of predicate availability.
Have you had a Pre-Submission (Q-Sub) meeting with the FDA? A Pre-Sub is the most direct way to get the agency's early read on your classification and pathway. It's not binding, but it significantly reduces the risk of a wrong-pathway investment.
What does your clinical evidence need to show? For 510(k), you need to demonstrate comparability. For PMA, you need to demonstrate safety and effectiveness. These are different evidentiary standards that require different study designs.
What is your funding timeline? If you have 18 months of runway and need human data before a Series B closes, a PMA pivotal trial isn't achievable in that window. But a well-designed early feasibility study that supports your IDE application can be.
When Founders Get This Wrong
The most common mistake is assuming a 510(k) pathway because a similar device exists on the market. Predicate selection is more nuanced than it looks. A device with the same intended use but meaningfully different technology may not qualify as substantially equivalent — and a Not Substantially Equivalent determination late in the process is expensive.
The second common mistake is under-designing the FIH study for a PMA pathway. Founders sometimes treat the early feasibility study as a standalone safety check rather than as the foundation for a pivotal trial. When the pivotal trial IDE application reaches the FDA, gaps in the early data create delays that could have been avoided.
Both mistakes come down to the same root cause: regulatory strategy that starts too late.
FAQs
What is the main difference between a 510(k) and a PMA?
A 510(k) clears a device by showing it is substantially equivalent to a legally marketed predicate. A PMA approves a device based on valid scientific evidence of safety and effectiveness, without relying on a predicate. PMA applies to Class III devices and requires a full clinical program; 510(k) applies primarily to Class II devices and often requires limited or no clinical data.
Does a 510(k) device need clinical trials?
Not always. Many 510(k) submissions rely on bench testing, biocompatibility data, and performance testing. Clinical data is required when bench testing alone can't establish substantial equivalence, or when the device's intended use involves a clinical performance claim that needs human data to support it.
What is an IDE and when do you need one?
An Investigational Device Exemption (IDE) is FDA authorization to use an investigational device in a clinical study. You need an IDE for any significant-risk device study conducted in the United States. For PMA devices, the IDE is the mechanism that allows you to collect the pivotal trial data the FDA requires for approval.
Can a Class II device require PMA?
In rare cases, yes. The FDA can require a Class II device to go through PMA if it determines that general and special controls aren't sufficient to provide reasonable assurance of safety and effectiveness. This is uncommon but worth confirming for novel device types.
What is the De Novo pathway and how does it differ from 510(k) and PMA?
De Novo is a classification pathway for novel, low-to-moderate-risk devices with no valid predicate. It creates a new device type and establishes the device as a predicate for future 510(k) submissions. It requires more documentation than a standard 510(k) but is less burdensome than PMA — making it the right route for genuinely first-of-kind devices that don't pose Class III risk.
How does my FDA pathway choice affect my first-in-human study design?
Your pathway determines the evidentiary standard your clinical data must meet. A 510(k) FIH study typically needs to confirm safety and support predicate comparisons, with narrower endpoints and smaller enrollment. A PMA FIH study is the first step in a longer clinical program and must be designed with the pivotal trial in mind from the start — including endpoints, patient population, and follow-up duration.
How long does PMA approval typically take compared to 510(k)?
The FDA's standard review period for a 510(k) is 90 days from acceptance, though total elapsed time is often longer. For PMA, the FDA has 180 days from filing acceptance to act, but the full development timeline from first-in-human to PMA approval for complex devices can span several years — including the time required to complete a pivotal trial.
Pathway selection is a regulatory decision with clinical, financial, and strategic consequences. The earlier you align your FIH study design to your intended submission, the less time and capital you spend collecting data that doesn't move your program forward.
If you're mapping your device's regulatory strategy and want to understand how a structured FIH program fits into that plan, learn more at bioaccessla.com.
Leave a Reply